Loading...
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
Canagliflozin — a sodium-glucose cotransporter 2 inhibitor used to treat type 2 diabetes — is associated with lower risk for heart failure admission relative to other diabetes drugs, suggests an observational study in The BMJ.
Using health insurance data, U.S. researchers studied nearly 80,000 adults with diabetes and without cardiovascular disease who began treatment with canagliflozin; a dipeptidyl peptidase-4 (DPP-4) inhibitor (e.g., saxagliptin); a glucagon-like peptide-1 (GLP-1) receptor agonist (e.g., liraglutide); or a second- or third-generation sulfonylurea (e.g., glimepiride). Canagliflozin recipients were matched with patients who began each of the other drug classes.
During follow-up, the incidence of heart failure admission was lower with canagliflozin (7.3–8.9 events per 1000 person-years) than with DPP-4 inhibitors (12.8 per 1000), GLP-1-receptor agonists (12.4), or sulfonylureas (14.4). A second primary endpoint — a composite of myocardial infarction or stroke — did not differ significantly between canagliflozin and the other groups.
The researchers conclude: "Our investigation shows the potential cardiovascular benefits of canagliflozin versus other diabetes drugs as used in routine care."
Comment
LINK(S):
The BMJ article (Free)
Background: NEJM Journal Watch Cardiology coverage of canagliflozin vs. placebo (Your NEJM Journal Watch subscription required)